» Articles » PMID: 34795859

Ugi Reaction Synthesis of Oxindole-Lactam Hybrids As Selective Butyrylcholinesterase Inhibitors

Overview
Specialty Chemistry
Date 2021 Nov 19
PMID 34795859
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Molecular hybridization is a valuable approach in drug discovery. Combining it with multicomponent reactions is highly desirable, since structurally diverse libraries can be attained efficiently in an eco-friendly manner. In this work, isatin is used as the key building block for the Ugi 4-center 3-component reaction synthesis of oxindole-lactam hybrids, under catalyst-free conditions. The resulting oxindole-β-lactam and oxindole-γ-lactam hybrids were evaluated for their potential to inhibit relevant central nervous system targets, namely cholinesterases and monoamine oxidases. Druglikeness evaluation was also performed, and compounds and exhibited great potential as selective butyrylcholinesterase inhibitors, at the low micromolar range, with an interesting predictive pharmacokinetic profile. Our findings herein reported suggest oxindole-lactam hybrids as new potential agents for the treatment of Alzheimer's disease.

Citing Articles

Multicomponent reactions driving the discovery and optimization of agents targeting central nervous system pathologies.

Campos-Prieto L, Garcia-Rey A, Sotelo E, Mallo-Abreu A Beilstein J Org Chem. 2024; 20:3151-3173.

PMID: 39669443 PMC: 11635293. DOI: 10.3762/bjoc.20.261.


Targeting Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2): Latest Insights on Synthetic Strategies.

Marques C, Brandao P, Burke A Molecules. 2024; 29(22).

PMID: 39598729 PMC: 11596329. DOI: 10.3390/molecules29225341.


The Ugi4CR as effective tool to access promising anticancer isatin-based α-acetamide carboxamide oxindole hybrids.

Marques C, Gonzalez-Bakker A, Padron J Beilstein J Org Chem. 2024; 20:1213-1220.

PMID: 38887573 PMC: 11181168. DOI: 10.3762/bjoc.20.104.


Recent developments on microwave-assisted organic synthesis of nitrogen- and oxygen-containing preferred heterocyclic scaffolds.

Tiwari G, Khanna A, Mishra V, Sagar R RSC Adv. 2023; 13(47):32858-32892.

PMID: 37942237 PMC: 10628940. DOI: 10.1039/d3ra05986c.


Ugi Four-Component Reactions Using Alternative Reactants.

Hooshmand S, Zhang W Molecules. 2023; 28(4).

PMID: 36838630 PMC: 9961709. DOI: 10.3390/molecules28041642.


References
1.
Veber D, Johnson S, Cheng H, Smith B, Ward K, Kopple K . Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002; 45(12):2615-23. DOI: 10.1021/jm020017n. View

2.
Wang H, Zhang H . Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer's Disease. ACS Chem Neurosci. 2018; 10(2):852-862. DOI: 10.1021/acschemneuro.8b00391. View

3.
Proschak E, Stark H, Merk D . Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds. J Med Chem. 2018; 62(2):420-444. DOI: 10.1021/acs.jmedchem.8b00760. View

4.
Williams A, Zhou S, Zhan C . Discovery of potent and selective butyrylcholinesterase inhibitors through the use of pharmacophore-based screening. Bioorg Med Chem Lett. 2019; 29(24):126754. PMC: 6953623. DOI: 10.1016/j.bmcl.2019.126754. View

5.
Daina A, Michielin O, Zoete V . SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017; 7:42717. PMC: 5335600. DOI: 10.1038/srep42717. View